AI and omics unlock personalized drugs and RNA therapies for heart disease

AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought “untreatable.”

2025-10-07

(Press-News.org) AI and omics unlock personalized drugs and RNA therapies for heart disease

AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought “untreatable.”

A new article published in Frontiers in Science says these tools could transform heart drug development and save lives—but that global, equitable health policy leadership is urgently needed.

Despite major advances in cardiovascular care, heart disease remains the world’s leading cause of death. This is partly because cardiovascular medicine still largely relies on broad-brush treatments that don’t account for the enormous diversity within cardiovascular diseases (CVDs). Although these one-size-fits-all treatments—like statins—help many patients, they do not work for everyone.

The new review calls for a fundamental shift in how heart drugs are discovered, developed, and tested. Using AI, omics, and big data to identify and design drugs for disease-related genes and proteins, this “innovation paradigm” could drive the development of truly personalized treatments for CVD.

“CVDs are likely to claim 26 million deaths per year by 2030, up from 19 million in 2020,” said lead author Prof Masanori Aikawa, from Brigham and Women's Hospital and Harvard Medical School. “This approach could usher in new drugs that succeed where conventional ones have failed—but global health leadership is needed to drive that transformation and ensure it saves lives worldwide.”

One promising avenue is RNA-based therapeutics. Unlike conventional drugs, which reach only a small percentage of all potential protein targets, RNA therapies can be designed to influence almost any gene. They may also be quicker to develop, and early trials already show their potential for lowering cholesterol more effectively than standard treatments.

“This is an exciting time for cardiovascular medicine,” said Prof Aikawa. “RNA therapies are already opening the door to tackle disease pathways long considered ‘undruggable,’ and with strong global leadership, we can bring new precision medicines to patients faster and save lives from CVD.”

Next-generation heart medicine

CVDs vary between patients in terms of their symptoms, underlying mechanisms, and how well they respond to treatment. Even patients with identical diagnoses present differently, which reflects the broad spectrum of our genes, environments, and lifestyles.

To better serve this variance, the authors say the new approach should harness such technologies as:

• omics approaches, which provide detailed information about molecules within cells, such as proteins (proteomics) and genes (genomics)

• systems biology, which looks at how networks of genes and proteins interact to shape disease

• AI, which can analyze disease pathways to identify new drug targets, and design new drugs targeted to specific proteins and genes.

The authors predict that, with sufficient investment and support, this innovation paradigm will give rise to a whole new generation of therapies—especially RNA-targeted and digitally designed drugs—that can intervene in disease pathways previously considered ‘undruggable.’ Such advances could dramatically reduce the time, cost, and failure rate involved in the development of cardiovascular drugs.

“There’s no single version of CVD, so to treat patients more effectively, we need bespoke medicines that reflect the broad spectrum of CVDs. This means harnessing technological advances to map the complex networks of genes, proteins, and pathways that differ between individuals—and identify how best to target them,” said senior-author Prof Joseph Loscalzo, from Brigham and Women's Hospital and Harvard Medical School. “This is how we make the ‘untreatable’ treatable: by spotting new drug targets within individual patients, and designing new molecules specifically for them.”

Bold investment; open science

But turning these tools into real treatments will take more than lab breakthroughs. The authors call for stronger collaboration between scientists, industry, and healthcare, alongside global policy leadership to ensure precision medicine reaches people everywhere.

“To save lives from CVD, we urgently need a new standard approach,” said co-author Dr Sarvesh Chelvanambi, from Brigham and Women's Hospital and Harvard Medical School. “That means bold investment, open science, and new partnerships across academia, industry, and healthcare. Right now, this paradigm isn’t in place—even in high-income countries. Global leadership is vital to mobilize the funding, resources, and policies that will make it a reality worldwide.”

The authors say that with the right leadership, precision medicine could finally change the course of the world’s leading killer.

-ENDS-

END

ELSE PRESS RELEASES FROM THIS DATE:

2023 ocean heatwave ‘unprecedented but not unexpected’

2025-10-07

The June 2023 heatwave in northern European seas was “unprecedented but not unexpected”, new research shows. During the heatwave, temperatures in the shallow seas around the UK (including the North Sea and Celtic Sea) reached 2.9°C above the June average for 16 days. While unprecedented since observations began, the study warns that rapid climate change means there is now about a 10% chance of a marine heatwave of this scale occurring each year. The June 2023 marine heatwave significantly disrupted phytoplankton blooms. Although its full impact ...

Johns Hopkins researchers develop AI to predict risk of US car crashes

2025-10-07

In a significant step towards improving road safety, Johns Hopkins University researchers have developed an A.I.-based based tool that can identify the risk factors contributing to car crashes across the United States and to accurately predict future incidents. The tool, called SafeTraffic Copilot, aims to provide experts with both crash analyses and crash predictions to reduce the rising number of fatalities and injuries that happen on U.S. roads each year. The work, led by Johns Hopkins ...

New drug combination offers hope for men with advanced prostate cancer

2025-10-07

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers. The Phase III AMPLITUDE trial, published in Nature Medicine, tested the addition of niraparib, a type of targeted cancer drug known as a PARP inhibitor1, to the standard treatment of abiraterone acetate and prednisone (AAP).2 The study focused on patients diagnosed with advanced prostate cancer where cells have spread to other parts of the body, who were starting their first ...

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

2025-10-07

LOS ANGELES — Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and a leading research center for diabetes and other life-threatening illnesses, have uncovered a gene called SMOC1 that plays a surprising role in the development of type 2 diabetes (T2D) by converting pancreatic cells that normally produce insulin into those that increase blood sugar. The findings, published in Nature Communications, identify an important new therapeutic target for T2D and ...

Powerful and precise multi-color lasers now fit on a single chip

2025-10-07

A few years ago, researchers in Michal Lipson’s lab noticed something remarkable. They were working on a project to improve LiDAR, a technology that uses lightwaves to measure distance. The lab was designing high-power chips that could produce brighter beams of light. “As we sent more and more power through the chip, we noticed that it was creating what we call a frequency comb,” says Andres Gil-Molina, a former postdoctoral researcher in Lipson’s lab. A frequency comb is a special type of light that contains many colors lined up next to each other in an orderly pattern, kind of like ...

Scientists agree chemicals can affect behavior, but industry workers more reluctant about safety testing

2025-10-07

Survey of 166 international experts highlights concerns about protecting human and wildlife health from environmental pollutants Less than a third of industry scientists support including behavioural tests in chemical safety assessments, compared to 80 per cent of academics and 91 per cent of government scientists Despite almost all scientists (97 per cent) agreeing that chemicals can affect wildlife behaviour, most testing is done by universities rather than chemical companies, leaving gaps ...

DNA nanospring measures cellular motor power

2025-10-07

Cells all require the transport of materials to maintain their function. In nerve cells, a tiny motor made of protein called KIF1A is responsible for that. Mutations in this protein can lead to neurological disorders, including difficulties in walking, intellectual impairment and nerve degradation. It’s known that mutations in KIF1A also result in a weakened motor performance, but this has been difficult to measure so far. Researchers including those from the University of Tokyo and the National Institute of Information and Communications Technology (NICT) in Japan have measured changes in the force of KIF1A using a nanospring, a tiny, coiled structure, ...

Elsevier Foundation and RIKEN launch “Envisioning Futures” report: paving the way for gender equity and women’s leadership in Japanese research

2025-10-07

A unique collaboration, the Elsevier Foundation and RIKEN, Japan’s premier research institute, have released “Envisioning Futures: Women’s Leadership and Gender Equity in Japanese Research,” a comprehensive report that shines a spotlight on the journeys, achievements and challenges faced by women research leaders in Japan. The report blends data-driven analysis with compelling personal narratives, offering a timely roadmap for institutional change and a call to action for the advancement of women in science and innovation. The report shows that despite Japan’s global reputation for technological ...

Researchers discover enlarged areas of the spinal cord in fish, previously found only in four-limbed vertebrates

2025-10-07

Four-limbed vertebrates, known as tetrapods, have two enlarged areas in their spinal cords. The two enlargements have a correlation with the forelimbs and hind limbs, respectively. These enlargements are thought to be caused by the complex muscular system and the rich sensory networks supplying nerves to the limbs. Meanwhile, it was long thought that fish had no enlarged areas in their spinal cords due to the absence of limbs. However, a recent study by scientists from Nagoya University in Japan has revealed that zebrafish, in fact, have enlarged areas in their spinal cords, although these areas are not visible ...

Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches

2025-10-07

HALIFAX, Nova Scotia, CANADA, 7 October 2025 -- In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr. Martin Alda illuminates how decoding psychiatric heterogeneity holds the key to revolutionizing mental health treatment worldwide. The interview reveals how this internationally acclaimed researcher transformed our global understanding of bipolar disorder by proving that what appears as one condition actually represents multiple genetically distinct disorders, fundamentally ...